Stoke Therapeutics unveils more data on studies of Dravet drug, hinting at improvements to cognition and behavior
Stoke Therapeutics presented more data on its investigational Dravet syndrome treatment on Tuesday morning, saying it helped reduce seizures and improve certain cognitive and behavioral functions, but the 45 mg data were well below analyst expectations and investors sent the stock $STOK down nearly 40% before the opening bell.
It’s still a limited look at the studies, though, and more data are needed from two open-label Phase I/IIa trials and an extension study before finalizing Phase III plans next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.